ATORX — Alligator Bioscience AB Share News
0.000.00%
Last trade - 00:00- SEK89.83m
- SEK103.14m
- SEK0.51m
Brief: Alligator Bioscience Q4 EBIT SEK -60.1 Million
Brief: Alligator Bioscience Announces Final Terms Of Rights Issue
Brief: Alligator Bioscience Carries Out Rights Issue Of About SEK 280 Mln
Brief: Alligator Bioscience EGM To Be Held On Monday, Jan 13, 2025
Brief: Alligator Says May Lay Off About 70% Of Current Workforce
Brief: Orion And Alligator Bioscience Amend Their Agreement Concerning Two Bispecific Antibodies
Brief: Alligator Bioscience Says Alg.Apv-527 Meets Phase 1 Trial Endpoints
Brief: Alligator Bioscience Q3 EBIT SEK -62 Million
Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data From Dose Escalation Phase Of Their Phase 1 Trial
Brief: Alligator Bioscience Q2 EBIT SEK -47.4 Million
Brief: Alligator Bioscience Reports Survival Benefit & Long Response Duration from Mitazalimab Phase 2 Study in First-Line Pancreatic Cancer
Brief: Alligator Bioscience: Primary Endpoint Of Optimize-1 Trial Was Met
Brief: Alligator Bioscience Appoints Johan Giléus As CFO
Brief: Alligator Bioscience Says Henlius Biotech Gets FDA IND Clearance For Phase 3 Initiation To Evaluate HLX22 (Ac101) In 1st Line HER2+ Advanced Gastric Cancer
Brief: Alligator Bioscience Q1 EBIT SEK -59.636 Million
Brief: Alligator And Orion Develop Option Under 2021 Collaboration And License Agreement
Brief: Alligator Raises About SEK 107.1 Mln In Rights Issue
Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data Of Dose Escalation Phase Of ALG.APV-527 Phase 1 Study
Brief: Alligator Carries Out Units Rights Issue, Bridge Loans